Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica

Importance

Despite the increased use of rituximab therapy in neuromyelitis optica spectrum disorder (NMOSD), the overall efficacy and safety of long-term rituximab treatment in a large group of patients is uncertain. Furthermore, the identification of a predictor of rituximab response is an important issue for assessing the individual risk-benefit of therapy and making treatment decisions.

Objective

To assess the long-term clinical efficacy and safety of rituximab treatment in patients with NMOSD and the influence of fragment c gamma receptor 3A (FCGR3A) polymorphisms on rituximab response.

Design, Setting, and Participants

A retrospective review of 100 patients with relapsing NMOSD treated with rituximab for at least 6 months, from February 1, 2006, to January 31, 2015, at the institutional referral center. After induction therapy, a single infusion of rituximab (375 mg/m²) as maintenance therapy was administered whenever a reemergence of CD27⁺memory B cells among peripheral blood mononuclear cells occurred. Using an allele-specific polymerase chain reaction–based method, the gene polymorphismsFCGR3A-V158F were assessed.

Main Outcomes and Measures

The primary end point was annualized relapse rate; disability (Expanded Disability Status Scale score), safety of rituximab treatment, event of insufficient memory B-cell depletion following rituximab, and time to retreatment of rituximab were secondary end points.

Results

By January 31, 2015, a total of 100 patients received repeated rituximab treatment during a median of 67 months. Of these patients, 41 had more than 5 years’ follow-up and 24 had more than 7 years’ follow-up. The annualized relapse rate was reduced significantly by 96% (mean [SD] annualized relapse rate of prerituximab vs postrituximab, 2.4 [2.0] vs 0.1 [0.6]) and disability improved or stabilized in 96% of patients. Rates of adverse events were generally stable. TheFCGR3A-F allele was associated with a risk of relapse while receiving rituximab treatment (additive model,P < .05; recessive model,P = .04; maximum,P = .03) and insufficient memory B-cell depletion (additive model,P = .03; recessive model,P = .03; maximum,P = .03).

Conclusions and Relevance

Repeated rituximab treatment for NMOSD was observed in an increasing number of patients and increasing duration of exposure and maintained good efficacy and a safety profile consistent with previous reports. The finding of a relationship betweenFCGR3Agenetic polymorphisms and rituximab response suggests the importance of individualized rituximab treatment strategies in NMOSD.